QX005N
Atopic Dermatitis, Prurigo Nodularis, CRSwNP, CSU, Asthma, COPD
Phase 2Active
Key Facts
Indication
Atopic Dermatitis, Prurigo Nodularis, CRSwNP, CSU, Asthma, COPD
Phase
Phase 2
Status
Active
Company
About Qyuns Therapeutics
Publicly traded biotech developing antibody therapies for autoimmune and allergic diseases with a pipeline targeting IL-4Rα, IL-17A, IL-23, and TSLP pathways.
View full company profile